[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

PT1372611E - Composicao farmaceutica compreendendo uma estaurosporina francamente soluvel em agua, um tensioactivo et um polimero soluvel em agua - Google Patents

Composicao farmaceutica compreendendo uma estaurosporina francamente soluvel em agua, um tensioactivo et um polimero soluvel em agua

Info

Publication number
PT1372611E
PT1372611E PT02732526T PT02732526T PT1372611E PT 1372611 E PT1372611 E PT 1372611E PT 02732526 T PT02732526 T PT 02732526T PT 02732526 T PT02732526 T PT 02732526T PT 1372611 E PT1372611 E PT 1372611E
Authority
PT
Portugal
Prior art keywords
water
soluble
polymer
freshly
tension
Prior art date
Application number
PT02732526T
Other languages
English (en)
Inventor
Andreas Ebner
Bruno Galli
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE2001117049 external-priority patent/DE10117049A1/de
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PT1372611E publication Critical patent/PT1372611E/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/70Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PT02732526T 2001-03-26 2002-03-26 Composicao farmaceutica compreendendo uma estaurosporina francamente soluvel em agua, um tensioactivo et um polimero soluvel em agua PT1372611E (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10114869 2001-03-26
DE2001117049 DE10117049A1 (de) 2001-04-05 2001-04-05 Zusammensetzung

Publications (1)

Publication Number Publication Date
PT1372611E true PT1372611E (pt) 2006-08-31

Family

ID=26008913

Family Applications (1)

Application Number Title Priority Date Filing Date
PT02732526T PT1372611E (pt) 2001-03-26 2002-03-26 Composicao farmaceutica compreendendo uma estaurosporina francamente soluvel em agua, um tensioactivo et um polimero soluvel em agua

Country Status (15)

Country Link
US (5) US20040077232A1 (pt)
EP (1) EP1372611B1 (pt)
JP (1) JP4330343B2 (pt)
CN (1) CN100350911C (pt)
AT (1) ATE326216T1 (pt)
AU (1) AU2002304784A1 (pt)
BR (1) BR0208306A (pt)
CA (1) CA2439097C (pt)
CY (1) CY1106159T1 (pt)
DE (1) DE60211494T2 (pt)
DK (1) DK1372611T3 (pt)
ES (1) ES2261671T3 (pt)
HK (1) HK1061515A1 (pt)
PT (1) PT1372611E (pt)
WO (1) WO2002076432A2 (pt)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003077883A2 (de) * 2002-03-15 2003-09-25 Kuyus Stiftung Zusammensetzung und verwendung derselben zur bildung eines schutzfilms auf nasenschleimhäuten
JO2897B1 (en) 2004-11-05 2015-09-15 نوفارتيس ايه جي Organic compounds
CN101516339B (zh) * 2006-08-16 2012-06-13 诺瓦提斯公司 制备高度结晶的治疗化合物的固体分散体的方法
US20090087460A1 (en) * 2007-10-02 2009-04-02 Hamamatsu Photonics K.K. Solid composition, microparticles, microparticle dispersion liquid, and manufacturing methods for these
JP5149585B2 (ja) * 2007-10-02 2013-02-20 浜松ホトニクス株式会社 微粒子分散液製造方法
JP5161528B2 (ja) * 2007-10-02 2013-03-13 浜松ホトニクス株式会社 パクリタキセル微粒子、パクリタキセル微粒子分散液、および、これらの製造方法
WO2009100176A2 (en) * 2008-02-07 2009-08-13 Abbott Laboratories Pharmaceutical dosage form for oral administration of tyrosine kinase inhibitor
WO2011000811A2 (en) * 2009-06-30 2011-01-06 Novartis Ag Organic compounds
WO2013024856A1 (ja) * 2011-08-17 2013-02-21 東レ株式会社 医療デバイスおよびその製造方法
US10478498B2 (en) 2014-06-20 2019-11-19 Reform Biologics, Llc Excipient compounds for biopolymer formulations
AU2015355226B2 (en) * 2014-12-02 2020-04-02 Minerva Neurosciences, Inc. Compositions comprising 2-((1-(2(4-Fluorophenyl)-2-oxoethyl)piperidin-4-yl)methyl)isoindolin-1-one for treating schizophrenia
KR20170084736A (ko) * 2016-01-12 2017-07-21 삼성디스플레이 주식회사 표시장치
JP2019527729A (ja) 2016-07-13 2019-10-03 リフォーム バイオロジクス、エルエルシー 治療用タンパク質製剤のための安定化賦形剤
US11642199B2 (en) * 2018-09-24 2023-05-09 3M Innovative Properties Company Dental appliance with cosmetic therapeutic aqueous solution
CN116370408A (zh) * 2020-06-17 2023-07-04 成都瑞沐生物医药科技有限公司 一种滴眼给药治疗黄斑水肿、视神经炎和非感染性眼内炎的眼用制剂
WO2024131725A1 (en) * 2022-12-19 2024-06-27 Shenzhen Pharmacin Co., Ltd. Topical pharmaceutical compositions and uses thereof

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3754082A (en) * 1970-06-11 1973-08-21 Richardson Merrell Inc Process and composition for botfly larvae eliminination
CA1141663A (en) * 1979-09-06 1983-02-22 Yukihisa Ishii Ophthalmic solution for intraocular pressure adjustment
JPS61194034A (ja) * 1985-02-25 1986-08-28 Teijin Ltd 経鼻投与用粉末状組成物
JPS632932A (ja) * 1986-06-23 1988-01-07 Teijin Ltd 経鼻投与用粉末状組成物
US5093330A (en) * 1987-06-15 1992-03-03 Ciba-Geigy Corporation Staurosporine derivatives substituted at methylamino nitrogen
US5213738A (en) * 1990-05-15 1993-05-25 L. Perrigo Company Method for making a capsule-shaped tablet
IT1245761B (it) * 1991-01-30 1994-10-14 Alfa Wassermann Spa Formulazioni farmaceutiche contenenti glicosaminoglicani assorbibili per via orale.
GB9325395D0 (en) * 1993-12-11 1994-02-16 Ciba Geigy Ag Compositions
WO1995022331A1 (en) * 1994-02-18 1995-08-24 Cephalon, Inc. Aqueous indolocarbazole solutions
EP0733358A3 (de) * 1995-03-21 1998-05-20 Novartis AG Intravenös applizierbare Nanosuspensionen
WO1998053828A1 (fr) * 1997-05-27 1998-12-03 Senju Pharmaceutical Co., Ltd. Preparations aqueuses contenant de l'israpafant
TW546151B (en) * 1997-07-23 2003-08-11 Senju Pharma Co Aqueous liquid pharmaceutical composition containing as main component benzopyran derivative
DE19813661A1 (de) * 1997-08-01 1999-02-04 Solvay Pharm Gmbh Gegen Racemisierung stabilisierte pharmazeutische Zubereitungen von Cilansetron
GB9903547D0 (en) * 1999-02-16 1999-04-07 Novartis Ag Organic compounds
US6190869B1 (en) * 1999-10-26 2001-02-20 Isis Pharmaceuticals, Inc. Antisense inhibition of protein kinase C-theta expression

Also Published As

Publication number Publication date
CY1106159T1 (el) 2011-06-08
ATE326216T1 (de) 2006-06-15
DE60211494D1 (de) 2006-06-22
JP2004534739A (ja) 2004-11-18
US20080287417A1 (en) 2008-11-20
WO2002076432A2 (en) 2002-10-03
US20040077232A1 (en) 2004-04-22
US20140303145A1 (en) 2014-10-09
CA2439097A1 (en) 2002-10-03
DE60211494T2 (de) 2006-10-12
US20140018346A1 (en) 2014-01-16
CN1499959A (zh) 2004-05-26
WO2002076432A3 (en) 2002-12-12
ES2261671T3 (es) 2006-11-16
EP1372611B1 (en) 2006-05-17
BR0208306A (pt) 2004-03-09
DK1372611T3 (da) 2006-09-18
JP4330343B2 (ja) 2009-09-16
HK1061515A1 (en) 2004-09-24
CN100350911C (zh) 2007-11-28
EP1372611A2 (en) 2004-01-02
AU2002304784A1 (en) 2002-10-08
US20160287707A1 (en) 2016-10-06
CA2439097C (en) 2010-10-12

Similar Documents

Publication Publication Date Title
CY1106159T1 (el) Φαρμακευτικη συνθεση που πepιλαμβανει πενιχρα υδατοδιαλυτη σταυροσπορινη, επιφανειοδραστικη ουσια και υδατοδιαλυτο πολυμepες
ATE544447T1 (de) Arzneistoffcoating mit hohem wirkstoffanteil sowie methoden zu dessen herstellung
ATE292453T1 (de) Antivirale arznei
NO20011721D0 (no) N-aralkylaminotetraliner som ligander for neuropeptid Y Y5 reseptor
AU4989997A (en) Soluble form osmotic dose delivery system
WO1998040069A3 (en) Stabilization of acid sensitive benzimidazoles with amino acid/cyclodextrin combinations
EP1589947B8 (en) Pharmaceutical formulation with an insoluble active agent for pulmonary administration
ES2155124T3 (es) Composiciones farmaceuticas liquidas a base de hormonas tiroideas.
CA2374877A1 (en) Pharmaceutical formulations and methods comprising intranasal morphine
ATE541562T1 (de) Ibuprofen-suspension
BR0210489A (pt) Formulação farmacêutica oral, processo para preparar a mesma, uso da mesa, e método para preparar um distúrbio cardiovascular em um paciente
SE0100200D0 (sv) New film coating
MY129450A (en) Pharmaceutical composition
DE60102590D1 (de) Darreichungsformen zur behandlung von oralen mykosen
WO2000069390A3 (en) Compositions for improving bioavailability of orally administered drugs
NO20023551D0 (no) Ibuprofen-inneholdende aktivt middel-preparat
BR0007452A (pt) Uso de melagatrano ou de um derivado farmaceuticamente aceitável ou pró-droga do mesmo, método de tratamento de inflamação, e, formulação farmacêutica para uso no tratamento de inflamação
ATE353224T1 (de) Abgabeeinrichtung für eine zusammensetzung einer pharmazeutisch wirksamen substanz
NZ520927A (en) Orally administered controlled delivery system for once daily administration of ciprofloxacin
SE9900177L (sv) Användning av en beredning innehållande myrsyra för framställning av ett läkemedel för behandling av vårtor, orsakade av Papillomavirus
UY27345A1 (es) Formulación farmacéutica.
RU99115222A (ru) Способ лечения терапевтически резистентных больных шизофренией